March 16, 2017 / 11:36 AM / 6 months ago

BRIEF-Proteon Therapeutics FY loss per share $1.72

March 16 (Reuters) - Proteon Therapeutics Inc:

* Proteon Therapeutics announces full-year 2016 financial results and changes to the ongoing phase 3 patency-2 clinical trial

* Proteon Therapeutics -expects its cash, cash equivalents and available-for-sale investments will be sufficient to fund its operations into Q3 of 2018

* Proteon Therapeutics Inc - expects to report top-line data in Q4 of 2018 for patency-2 trial

* Proteon Therapeutics Inc - if patency-2 trial is successful, Proteon expects to submit a bla in 2019

* Proteon Therapeutics -FY loss per share $1.72 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below